What separates these four aging options?
We compare NAD+, MOTS-c, sermorelin and GHK-Cu by what they are and what has been studied, rather than giving unlike evidence a single score.
Juventa Peptides may earn money when readers become Promise patients.
Compare the question before the compound.
“Longevity peptide” is a loose label, rather than a finding from a trial. NAD+ is an enzyme helper (coenzyme), not a peptide. The useful comparison begins with the body’s signal, then asks what material was studied, in what setting and for which outcome.
There is no common human trial here that tests all four as alternatives for the same aging concern. A side-by-side table can organize reading. It cannot produce a winner by making unlike research look equally certain.
| Option | Age observation | What it is | Research setting | Important limit |
|---|---|---|---|---|
| NAD+ | Lower tissue NAD+ with age | A helper for cell chemistry; not a peptide | Small direct-administration studies; separate oral precursor trials | A blood change does not establish a lasting aging benefit. |
| MOTS-c | Lower circulating levels in older men; higher muscle levels | A short chain of protein building blocks, encoded in the cell’s energy-producing structures | Cell and mouse treatment work; natural measurements in people | Human treatment and safety evidence remain missing. |
| Sermorelin | Smaller growth-hormone output with age | Part of the signal prompting growth-hormone release | Former childhood use and small, short adult hormone studies | An adult hormone response is not an established longevity result. |
| GHK-Cu | Less GHK in blood’s liquid portion with age | GHK bound to copper | Cell and animal work with attention to the peptide form | Free GHK and GHK-Cu findings cannot be treated as interchangeable. |
A lower level can be a clue in several ways.
The NAD+ aging work concerns changes within tissues. The MOTS-c study in men is more complicated than a general shortage: the older group had lower circulating levels and higher muscle levels. Blood and muscle do not give the same answer just because the same peptide is being measured.
Growth hormone is released in pulses. GHRH (growth hormone-releasing hormone) prompts this release. Research links this signaling change with age. Sermorelin is related to that releasing signal; it is not growth hormone. The GHK aging review describes lower plasma GHK, while GHK-Cu is the copper-bound complex. Each row requires its own translation before there can be a sensible treatment question.
A human study still needs to fit the claim.
NAD+ discussions often bring together direct administration and oral precursors, substances used to make NAD+ in the body. Evidence about one is not automatically evidence about the other. Similarly, natural MOTS-c measurements in people do not show the effects of administering MOTS-c.
Sermorelin’s adult literature can include hormone measurements and studies of closely related GHRH fragments. Its older childhood approval was for a different population and purpose. Neither type of evidence demonstrates that an otherwise healthy adult gains a longer life from treatment.
GHK research includes free peptide as well as copper-bound material, cells and animals as well as people. A human cell experiment is not a human clinical study. The phrase “human research” needs that extra question about whether a person or a laboratory sample was actually involved.
Safety is not a single score either.
Missing evidence cannot sensibly earn a favorable safety grade. MOTS-c has substantial gaps in human safety information. Injected GHK-Cu raises a different set of questions from a cosmetic preparation. Sermorelin involves the growth-hormone system, and direct NAD+ administration adds delivery and preparation questions to the normal biology of a coenzyme.
The FDA’s compounding discussion applies across the prescription route: compounded medicines prepared for these prescriptions are not FDA-approved. Pharmacy preparation is not a clinical finding, and the evidence does not become stronger because a product appears beside another one in a directory.
Let the table lead to the right reading.
The NAD+ page is useful for distinguishing the molecule from its precursors. The MOTS-c page separates animal experiments from observations in people. The sermorelin page handles the former approval and the adult question. The GHK-Cu page keeps the measured peptide distinct from its copper complex.
Promise Peptides lists all four of these options for U.S. prescription inquiries. The licensed provider, not this table, decides whether any belongs in a person’s care. The compounded medicines lack FDA approval. A choice can reasonably remain undecided after reading four product pages.
A reader may finish with fewer assumptions rather than a preferred compound. That is progress. The comparison is doing its job when it makes the next question more specific, including the question of whether any of these options fits the concern in the first place.
A question can be the next step.
Promise Peptides connects U.S. patients with licensed U.S. providers who examine every request and decide whether prescribing is appropriate. The review may find that a person does not qualify. Access differs with the patient’s state and the treatment. Licensed U.S. compounding pharmacies prepare prescriptions; compounded medicines prepared for these prescriptions are not FDA-approved.
Promise’s LegitScript certification does not give a medicine FDA approval.